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Abstract 25 
Objectives: Although azole antifungals are considered to be fungistatic, miconazole 26 
has fungicidal activity against planktonic Candida albicans cells, presumably 27 
associated with the induction of reactive oxygen species (ROS) production. Only few 28 
data are available concerning the effect of miconazole against sessile Candida 29 
albicans cells. In the present study, the fungicidal activity of miconazole against in 30 
vitro grown mature Candida biofilms and its relationship with the induction of ROS 31 
and ROS-dependent apoptosis were examined.  32 
 33 
Methods: The effect of miconazole on mature biofilms formed by ten Candida 34 
albicans strains and five strains from other Candida species was evaluated by plate 35 
counting and measuring the level of ROS induction. MIC tests were performed in the 36 
absence and presence of ascorbic acid, a quencher of ROS. The apoptotic population 37 
in C. albicans cells was determined using Annexin-Cy3. 38 
 39 
Results: Miconazole showed a significant fungicidal effect against all mature Candida 40 
biofilms tested and caused elevated ROS levels, both in planktonic and sessile cells. 41 
Addition of ascorbic acid drastically reduced these levels. While ROS quenching 42 
decreased the susceptibility to miconazole of planktonic cells of most Candida strains, 43 
no reduced fungicidal activity of miconazole against biofilms was observed. 44 
Miconazole did not cause a significant increase in apoptosis. 45 
 46 
Conclusions: ROS levels increased in all Candida biofilms upon addition of 47 
miconazole. However, ROS induction was not the only factor that underlies its 48 
fungicidal activity, as quenching of ROS did not lead to an enhanced survival of 49 
 3 
biofilm cells. ROS-induced apoptosis was not observed in C. albicans cells after 50 
miconazole treatment.51 
 4 
Introduction 52 
Candida species are frequently associated with nosocomial infections in 53 
immunocompromised hosts.1 Device-related infections caused by this organism often 54 
involve biofilm formation, a process in which planktonic yeast cells adhere to a biotic 55 
or abiotic surface, ultimately resulting in the formation of a complex three-56 
dimensional structure of yeast cells, filaments and extracellular polymeric matrix.2,3 57 
There are profound differences between planktonic and sessile cells, including an 58 
increased tolerance of the latter towards antifungal agents.4 59 
Azole antifungals are widely used to treat infections with Candida spp. These 60 
compounds inhibit the 14α-demethylation of lanosterol by interacting with 61 
cytochrome P450, a crucial enzyme in the ergosterol biosynthetic pathway. The 62 
resulting decrease of ergosterol levels and the accumulation of toxic sterol 63 
intermediates in the cytoplasmic membrane lead to growth inhibition.5 Miconazole 64 
(an imidazole) has reportedly a higher in vitro activity against planktonic Candida 65 
albicans cells than the more recently developed and presumably more active 66 
fluconazole (a triazole).6-8 However, few data are available about the effect of 67 
miconazole against Candida biofilms. A fungicidal activity was observed for 68 
miconazole on C. albicans biofilms, but only in young (2 – 6h) biofilms.9 Recent 69 
research has shown that the fungicidal activity of miconazole against planktonic C. 70 
albicans cells is related to the induction of reactive oxygen species (ROS). Although 71 
the exact mechanism of this enhanced ROS accumulation is not completely 72 
understood, combined inhibition of catalase and peroxidase, as well as changes in the 73 
actin cytoskeleton appear to be involved.7,8 It is well known that anti-oxidants can act 74 
as a reductant for ROS. Anti-oxidative compounds are important for the prevention of 75 
peroxidation and free radical accumulation.10 Furthermore, ROS are inducers of 76 
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apoptosis.11 Programmed cell death was observed in Saccharomyces cerevisiae 77 
exposed to different types of oxidative stress.12,13 Hyperactivation of the RAS-78 
signaling pathway by stabilization of the actin cytoskeleton leads to an increase in 79 
cAMP, followed by the loss of the mitochondrial membrane potential and the 80 
accumulation of ROS, ultimately leading to apoptosis.14 Apoptosis is also induced in 81 
C. albicans upon treatment with low doses of H2O2, acetic acid or amphotericin B.15  82 
The aim of the present study was to investigate the activity of miconazole against 83 
Candida biofilms. To this end, the effect of miconazole and fluconazole against 84 
mature biofilms of ten C. albicans strains and five strains belonging to other Candida 85 
species was compared. ROS levels were determined in miconazole-treated and 86 
untreated mature Candida biofilms to verify whether there is a correlation with the 87 
activity of miconazole. Finally, we investigated whether increased apoptosis 88 
contributes to the antimicrobial effect of miconazole. 89 
 90 
Materials and methods 91 
Strains 92 
The following strains were used: C. albicans SC5314 (ATCC MYA-2876) (American 93 
Type Culture Collection, Teddington, UK), C. albicans ATCC 10231, C. albicans 94 
IHEM 10284 (Institute of Hygiene and Epidemiology-Mycology Section, Brussels, 95 
Belgium), C. albicans IHEM 9559, C. albicans NCYC 1467 (National Collection of 96 
Yeast Cultures, Norwich, UK), C. albicans MUCL 29800 (Mycothèque de 97 
l'Université Catholique de Louvain, Louvain-la-Neuve, Belgium), C. albicans MUCL 98 
29903, C. albicans MUCL 29981, C. albicans MUCL 29919, C. albicans MUCL 99 
30112, Candida dubliniensis IHEM 14280, C. glabrata MUCL 15664, Candida 100 
krusei IHEM 1796, Candida parapsilosis IHEM 3270 and Candida tropicalis IHEM 101 
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4225. A stock culture of all these strains was kept in Microbank Tubes (Pro-Lab 102 
Diagnostics, Richmond Hill, ON, Canada) at -80°C. Cells were routinely transferred 103 
to Sabouraud Dextrose Agar (SDA) (Oxoid, Basingstoke, UK) plates or Sabouraud 104 
Dextrose Broth (SDB) (Oxoid) and incubated at 37°C for 24 h. 105 
 106 
Biofilm formation on silicone disks 107 
Candida biofilms were grown on sterile silicone disks (4 mm thickness and 13 mm in 108 
diameter) in a 24-well microtiter plate (TPP, Trasadingen, Switzerland). Silicone 109 
sheets were prepared from a medical grade silicone rubber kit (Q7-4735; Dow 110 
Corning Corp., Midland, MN, USA), according to the manufacturer’s instructions. 111 
The disks were punched from the sheets, washed in 2% RBS 35 detergent (Sigma-112 
Aldrich, St. Louis, MO, USA) and in MilliQ water (Millipore, Billerica, MA, USA) 113 
and autoclaved. Inoculum suspensions were prepared by incubating the cells in SDB 114 
for 16 h at 37°C. After removing the supernatant, the cells were washed three times 115 
with and finally resuspended in 1 mL 0.9% (w/v) NaCl (Novolab, Geraardsbergen, 116 
Belgium). This inoculum was further diluted with yeast nitrogen base 0.1x (YNB, 117 
BD, Franklin Lakes, USA) supplemented with 5 mM glucose (Sigma-Aldrich) to 118 
yield an optical density of 0.07 at a wavelength of 600 nm. One mL of a 1:100 119 
dilution of the inoculum in YNB 0.1x was added to each well containing a silicone 120 
disk and the 24-well microtiter plates were incubated for 1 h at 37°C. Subsequently, 121 
the silicone disks were rinsed three times with 1 mL 0.9% (w/v) NaCl to remove non-122 
adherent cells and aseptically transferred to a new well. Following the addition of 1 123 
mL of diluted YNB (0.004x with final glucose concentration 0.2 mM) to each well, 124 
the plates were further incubated for 24 h at 37°C. 125 
 126 
 7 
Biofilm formation in 96-well microtiter plates 127 
Candida biofilms were grown in round-bottomed 96-well microtiter plates (TPP), as 128 
described previously,16 with an adhesion phase of 1 h followed by a growth phase of 129 
24 h (both at 37°C in SDB). 130 
 131 
Treatment of biofilms with antifungal agents 132 
The silicone disks containing the mature biofilms were transferred to a new 24-well 133 
microtiter plate. One mL of a solution of fluconazole (Diflucan, Pfizer, Brussels, 134 
Belgium) or miconazole nitrate (Certa, Braine–l’Alleud, Belgium) (final 135 
concentration 5 mM, corresponding to 1531 mg/L for fluconazole and 2081 mg/L for 136 
miconazole) in PBS (phosphate buffered saline) with 2% DMSO (Sigma-Aldrich) was 137 
added to the biofilms. Appropriate controls were also included. The plates were 138 
incubated at 37°C for 24 h. The silicone disks were subsequently washed three times 139 
with 1 mL 0.9% (w/v) NaCl. The number of colony forming units (cfu) on each 140 
silicone disk was determined by pour plating. To this end, the silicone disks with 141 
biofilms were transferred to 10 mL of SDB and biofilm cells were removed from the 142 
silicone by three cycles of 30 s of sonication and 30 s of vortex mixing. With this 143 
procedure, all sessile cells were removed from the silicone disks and clumps of cells 144 
were broken apart.17 Serial tenfold dilutions of the resulting cell suspension were 145 
made and 1 mL of each dilution was plated and SDA was added, resulting in a lower 146 
limit of detection of 10 cfu per disk. Plates were incubated for 24 h at 37°C, after 147 
which the number of cfu per disk was calculated by counting colonies on the plates. 148 
For each strain and treatment, biofilms formed on at least three silicone disks in at 149 
least three independent experiments (n > 9) were included. 150 
 151 
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Detection of ROS 152 
Mature biofilms formed in round bottomed 96-well microtiter plates were rinsed with 153 
100 µL 0.9% (w/v) NaCl and treated for 24 h at 37°C with 100 µL of a miconazole 154 
suspension (5 mM in PBS with 2% DMSO). Appropriate controls were included and 155 
incubated under identical conditions. ROS accumulation was measured in a 156 
fluorometric assay using 2’,7’-dichlorofluorescein diacetate (DCFHDA) (Invitrogen, 157 
Carlsbad, CA, USA).6 To this end, biofilms were incubated with 10 µM DCFHDA, 158 
simultaneously with the antifungal treatment. Fluorescence was measured after 24 h 159 
incubation using a Wallac Victor Multilabel Counter (Perkin Elmer, Wellesley, MA, 160 
USA) (λEX = 485 nm; λEM = 535 nm). Values obtained were corrected for background 161 
fluorescence (measured in the absence of cells) and compared to those obtained with 162 
untreated biofilms. ROS levels were quantified in duplicate on at least three biofilms 163 
(n > 6) for each strain. To determine whether fluorescence is generated in the 164 
extracellular environment or intracellularly, the entire content of the well (supernatant 165 
and biofilm) was removed and cells were separated from the supernatant by 166 
centrifugation. The fluorescence of the supernatant and of the resuspended sessile 167 
cells in PBS was measured separately, as described above. 168 
 169 
Influence of anti-oxidants on miconazole-treated biofilms 170 
A set of anti-oxidative compounds was used to investigate their possible protective 171 
effect against miconazole activity, including cysteine (0.025% w/v and 0.25% w/v) 172 
(Sigma-Aldrich), mannitol (10 mM and 100 mM) (Merck, Darmstadt, Germany), 173 
glutathione (1.5 mM and 15 mM) (Sigma-Aldrich), ascorbic acid (10 mM and 100 174 
mM) (Merck) and pyrrolidinedithiocarbamate (PDTC) (10 µM and 1 mM) (Sigma-175 
Aldrich). The level of ROS was determined in miconazole-treated biofilms using 176 
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DCFHDA (10 µM) in the presence and absence of the anti-oxidants. The number of 177 
cfu on silicone disks of C. albicans SC5314 treated with miconazole in combination 178 
with the selected anti-oxidative compounds was determined by plating in at least three 179 
independent experiments on at least three silicone disks for each condition (n > 9). 180 
 181 
Antifungal susceptibility assay 182 
The minimal inhibitory concentration (MIC) of miconazole in the presence and 183 
absence of ascorbic acid (10 mM) was determined according to the protocol of the 184 
European Committee on Antimicrobial Susceptibility Testing.18 The medium used for 185 
these experiments was RPMI-1640 2x with L-glutamine and without sodium 186 
bicarbonate (Sigma-Aldrich), supplemented with 2% w/v glucose (Sigma-Aldrich) 187 
and buffered to pH 7.0 with MOPS (Sigma-Aldrich). Flat-bottomed 96-well microtiter 188 
plates were inoculated with Candida to obtain 5x105 cells per mL in each well. After 189 
24 h incubation at 35°C, the absorbance was measured at a wavelength of 590 nm 190 
using a Wallac Victor microtiter plate reader (Perkin Elmer). DCFHDA (10 µM) was 191 
also added to each well and the absorbance measurement was immediately followed 192 
by a measurement of fluorescence (λEX = 485 nm; λEM = 535 nm). 193 
 194 
Detection of apoptosis 195 
To investigate a possible apoptosis inducing effect of miconazole on C. albicans 196 
SC5314 biofilms the Apoptosis Detection Kit Annexin V-CY3 (Sigma-Aldrich) was 197 
used. This test allows to differentiate between living (green fluorescence), necrotic 198 
(red fluorescence) and apoptotic cells (green and red fluorescence). Biofilms were 199 
grown in 96-well microtiter plates and treated with miconazole, as described above. 200 
Sessile cells were removed and diluted 1:10 in PBS, after which 50 µL was spotted on 201 
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a microscope slide and left at room temperature, allowing the cells to be adsorbed to 202 
the slide. The adsorbed cells were carefully washed three times with binding buffer 203 
(supplied with the apoptosis kit) and treated with a mixture of 6-carboxyfluorescein 204 
diacetate (500 µM) and annexin V-Cy3 conjugate (1 mg/L) for 10 min. Excess 205 
labelling agent was removed by washing the cells three times with binding buffer. C. 206 
albicans biofilms treated with acetic acid (60 mM and 300 mM) and hydrogen 207 
peroxide (5 mM and 25 mM) were included as positive controls in this assay. 208 
Apoptosis in planktonic C. albicans SC5314 cells was also tested. Therefore 209 
overnight cultures were treated with miconazole (10 x MIC) for 24h and compared to 210 
untreated planktonic cultures. The staining procedure was performed as described 211 
above for sessile cells. Results were observed using a fluorescence microscope 212 
(Olympus BX40, Olympus, Tokyo, Japan). For each condition, between 241 and 1174 213 
cells were photographed and co-localisation of the fluorescein and Cy3 fluorescence  214 
signal was quantified on a cell per cell basis with an in house developed image 215 
processing program based on Matlab to differentiate between living, necrotic and 216 
apoptotic cells.  217 
 218 
Statistical analysis 219 
Statistical analysis was performed using SPSS 16.0 software. The non-parametric 220 
Mann-Whitney test was used to compare the results.  221 
 222 
Results 223 
Effect of azoles on Candida biofilms 224 
The effect of fluconazole and miconazole on Candida biofilms formed on silicone 225 
disks was determined for 15 strains (Figure 1). Untreated biofilms contained 105-106 226 
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cfu/disk depending on the strain tested. Treatment with fluconazole did not result in a 227 
significant reduction in cfu. In contrast, treatment with miconazole resulted in a 228 
substantial reduction (ranging from 89.3% to 99.1% ; p < 0.05) in the number of cfu 229 
recovered from the disks for all strains investigated. The lowest reductions were 230 
observed for C. parapsilosis IHEM 3270 (89.3%) and C. tropicalis IHEM 4225 231 
(90.3%) and the highest reductions were observed for C. albicans MUCL 30112 232 
(99.1%)  and C. albicans IHEM 10284 (99.1%).  233 
Our results showed only a fungistatic effect for fluconazole, whereas miconazole 234 
showed fungicidal activity against Candida biofilms. 235 
 236 
ROS accumulation in miconazole-treated biofilms 237 
Accumulation of ROS following treatment with miconazole was measured using 238 
DCFHDA. As the conversion of this dye depends on the number of metabolically 239 
active cells in the biofilm, results were normalized to the number of cfu/disk. 240 
Treatment with miconazole resulted in a significant increase of ROS accumulation for 241 
all strains investigated (p < 0.005) (Figure 2). No ROS accumulation could be 242 
observed for untreated C. dubliniensis IHEM 14280, C. glabrata MUCL 15664 and 243 
C. parapsilosis IHEM 3270 biofilms. In contrast, all untreated C. albicans biofilms 244 
tested showed a basal ROS accumulation. A remarkable high fluorescence could be 245 
observed for C. albicans MUCL 30112. The highest increases (more than 100-fold) in 246 
ROS accumulation after miconazole treatment could be observed for C. albicans 247 
MUCL 29919, C. albicans IHEM 9559 and C. albicans MUCL 29800. The lowest 248 
impact of miconazole treatment was detected for C. tropicalis IHEM 3270 (2-fold 249 
increase) and C. albicans 1467 (7-fold increase). Measurements were also carried out 250 
separately in sessile C. albicans SC5314 cells and in the supernatant. The ROS-251 
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induced increase in fluorescence was only observed for the cells and not for the 252 
supernatant (data not shown), indicating an intracellular origin. 253 
In conclusion, miconazole caused a significant intracellular increase of ROS 254 
accumulation in all Candida strains investigated. 255 
 256 
Effect of anti-oxidants on miconazole-treated biofilms 257 
The effect of the addition of five compounds with anti-oxidative properties on 258 
miconazole-treated C. albicans SC5314 biofilms was investigated using DCFHDA (n 259 
> 9 for each treatment). Only cysteine (0.25% w/v), glutathione (15 mM), PDTC (10 260 
µM) and ascorbic acid (10 mM and 100 mM) significantly reduced (p < 0.05) 261 
miconazole-induced ROS accumulation (Figure 3). However, addition of anti-262 
oxidants to miconazole-treated biofilms did not result in a statistically significant 263 
increase in survival (Figure 3). Ascorbic acid (10 mM) was selected to further 264 
examine the effect of ROS quenchers on other miconazole-treated Candida biofilms. 265 
The addition of ascorbic acid did not significantly increase the number of cfu on the 266 
silicone disks, but resulted in a reduction of ROS accumulation following treatment 267 
with miconazole for all strains tested (Table 1). This reduction was statistically 268 
significant (p < 0.05) when compared to biofilms treated with miconazole alone (n > 9 269 
for each strain), except for C. albicans MUCL 30112, MUCL 29919 and C. glabrata 270 
MUCL 15664. 271 
Ascorbic acid reduced the miconazole-induced ROS accumulation in sessile cells, but 272 
did not cause an enhanced survival.  273 
  274 
Effect of ascorbic acid on the susceptibility of planktonic cells 275 
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Miconazole also induced ROS accumulation in planktonic Candida cultures. Addition 276 
of ascorbic acid to planktonic cultures, incubated with miconazole reduced ROS 277 
production (47.8% to 89.9% reduction) for all strains tested (data not shown). The 278 
MIC of miconazole increased 2 to 64 fold for most strains following the addition of 279 
ascorbic acid. This increase was not observed for strains with an intermediate (0.125 280 
mg/L) MIC (C. albicans IHEM 10284 and MUCL 29919) and for most strains with a 281 
high (1.0 – 4.0 mg/L) MIC (C. glabrata MUCL 15664, C. krusei IHEM 1796 and C. 282 
parapsilosis IHEM 3270) (Table 2). 283 
For planktonic cells of most strains the addition of ascorbic acid reduced the ROS 284 
accumulation and the susceptibility to miconazole.  285 
 286 
Apoptosis in miconazole-treated planktonic and sessile C. albicans cells 287 
To determine whether the effect of miconazole was due to increased apoptosis, we 288 
quantified the number of apoptotic cells in treated and untreated biofilms and 289 
planktonic cultures (see supplementary data). Untreated planktonic C. albicans 290 
SC5314 cultures contained 14.0% + 7.0% apoptotic cells, which was not significantly 291 
different from miconazole-treated cells (14.6% + 4.5%). In contrast, a slight but not 292 
significant increase in the number of necrotic cells could be observed when planktonic 293 
cells were treated with miconazole (13.2% + 3.6%) compared to untreated cells (7.5% 294 
+ 2.3%). Untreated C. albicans SC5314 biofilms contained 9.7% + 4.0% apoptotic 295 
cells. A slight increase was observed following treatment with miconazole alone 296 
(14.4% + 11.5%) or in combination with ascorbic acid (18.5% + 6.5%). However, 297 
these increases were not significant. In contrast, the fraction of necrotic cells 298 
increased significantly (p < 0.05) compared to the untreated biofilms (8.9% + 3.7%) 299 
following treatment with miconazole alone (25.1% + 1.9%) or in combination with 300 
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ascorbic acid (32.7% + 8.6%). Low concentrations of acetic acid (60 mM) and 301 
hydrogen peroxide (5 mM) resulted in a significant increase (p < 0.05) in the fraction 302 
of apoptotic cells (34.6% + 5.1% and 20.6% + 5.2%, respectively). The hydrogen 303 
peroxide-treated biofilms also showed a significant increase in the amount of necrotic 304 
cells (26.1% + 3.5%). 305 
Miconazole did not result in increased apoptosis in planktonic or in sessile Candida 306 
cells. 307 
 308 
Discussion 309 
In the present study the antifungal activity of miconazole against Candida biofilms 310 
was investigated. 311 
Results from our study showed that miconazole, unlike fluconazole, has a pronounced 312 
anti-biofilm effect against C. albicans and other Candida spp. It should be noted that 313 
the antifungal concentration used in our in vitro experiments (5 mM) was higher than 314 
the common therapeutic in vivo concentrations. However, this high concentration is 315 
achievable during antifungal lock therapy,19,20 and allowed us to investigate the 316 
mechanism of action of miconazole. 317 
We observed that the accumulation of ROS was strongly increased in sessile Candida 318 
cells treated with miconazole, indicating that ROS may be responsible for the 319 
fungicidal effect. ROS are generally described as important inducers of apoptosis in 320 
yeasts,10 but ROS induced by treatment with miconazole did not cause an increase in 321 
programmed cell death in sessile C. albicans cells. The majority of cells killed by 322 
miconazole were necrotic. 323 
The addition of ascorbic acid to miconazole-treated Candida biofilms considerably 324 
reduced ROS accumulation for all strains. Surprisingly, this did not lead to a reduction 325 
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of the fungicidal activity of miconazole. Sessile Candida cells are reportedly more 326 
tolerant to oxidative stress than their planktonic counterparts.21 This inherent tolerance 327 
may explain why several anti-oxidative compounds did not result in an additional 328 
protection. Furthermore, previous studies have shown that prior to the induction of 329 
ROS miconazole affects the organization of the actin cytoskeleton in yeasts.8 The 330 
coupling of mitochondria to the actin cytoskeleton might lead to an association of 331 
actin with channels in the mitochondrial membranes. The opening of these channels is 332 
followed by reduction of the membrane potential and finally the release of ROS into 333 
the cytoplasm.22 The targeting of the actin cytoskeleton by miconazole may have 334 
other effects, which are not counteracted by ascorbic acid. Alternatively, a yet 335 
unknown mechanism may contribute to the fungicidal activity of miconazole against 336 
sessile Candida cells.  337 
An increase in ROS accumulation caused by miconazole treatment was also observed 338 
in all planktonic Candida cultures tested, confirming earlier observations in C. 339 
albicans.6,7 The addition of ascorbic acid to miconazole-treated planktonic Candida 340 
cells reduced ROS induction for all strains. Furthermore, a simultaneous decrease in 341 
susceptibility to miconazole was observed for most strains, which confirmed earlier 342 
findings concerning the protective effect of anti-oxidants during miconazole 343 
treatment.6 However, we demonstrated that the protective effect of ascorbic acid was 344 
limited in case of strains with intermediate to high MICs for miconazole. 345 
Our data suggest that miconazole may be useful for the treatment of biofilm-related 346 
Candida infections. We have also shown that ROS induction is probably not directly 347 
responsible for the reduction of the number of cfu. So far, the basis for the fungicidal 348 
activity of miconazole remains unclear and further investigations are needed. 349 
 350 
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Figure legends 423 
 424 
Figure 1. Number of colony forming units (logarithmic) per silicone disk of 425 
Candida biofilms in the presence and absence of antifungals. Black bars, untreated 426 
mature biofilms; grey bars, mature biofilms treated with 5 mM fluconazole; white 427 
bars, mature biofilms treated with 5 mM miconazole. Data presented are the mean 428 
and SEM of at least three independent experiments on at least three biofilms (n > 429 
9). Statistical analysis with Mann-Whitney Test indicated significant differences 430 
in biofilm biomass between miconazole-treated and untreated biofilms for all 431 
strains tested (p < 0.05), but not between fluconazole-treated and untreated 432 
biofilms. 433 
 434 
Figure 2. Accumulation of ROS expressed as fluorescence per 1000 cells in 435 
mature Candida biofilms in the presence and absence of miconazole. Black bars, 436 
untreated mature biofilms; grey bars, mature biofilms treated with 5 mM 437 
miconazole. Data presented are the mean and SEM of two independent 438 
experiments on at least three biofilms (n > 6). Statistical analysis with Mann-439 
Whitney Test indicated a significant difference (p < 0.05) in fluorescence between 440 
miconazole-treated and untreated biofilms. * Fluorescence below background 441 
level 442 
 443 
Figure 3. Number of cfu of C. albicans SC5314 biofilms (left Y-axis) and ROS 444 
accumulation (right Y-axis) following treatment with miconazole in the absence 445 
or presence of anti-oxidants. Black bars, log cfu per silicone disk; grey bars, 446 
fluorescence. Data presented are the mean and SEM of at least three independent 447 
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experiments on at least three biofilms (n > 9). All treated biofilms showed a 448 
significant increase  (p < 0.05) in cfu compared to the control. Significant 449 
reductions (p < 0.05) in ROS accumulation compared to the control are marked 450 
with an asterisk.451 
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Table 1. Number of cfu of Candida biofilms and ROS accumulation after miconazole treatment and the addition of ascorbic acid (10 mM). Plate 452 
counts correspond to the mean + SEM of at least three independent experiments on at least three silicone disks (n > 9). There was no significant 453 
increase in cfu after the addition of ascorbic acid compared to miconazole-treated biofilms without ascorbic acid. Fluorescence results 454 
correspond to the mean + SEM of two independent experiments on three biofilms (n = 6). Statistically significant reductions (p < 0.05) in ROS 455 
accumulation are marked with an asterisk. 456 
 457 
 458 
 PLATING 
(log cfu / silicone disk) 
FLUORESCENCE 
(% compared to miconazole treatment 
without ascorbic acid) 
C. albicans SC5314 4.13  + 0.41 10.4  + 2.3* 
C. albicans MUCL 29800 2.00  + 0.02 32.2  + 7.7* 
C. albicans MUCL 29981 2.99  + 0.20 30.7  + 4.2* 
C. albicans MUCL 29903 3.47  + 0.04 60.3  + 14.1* 
C. albicans MUCL 30112 2.53  + 0.31 17.9  + 5.6* 
C. albicans NCYC 1467 4.16  + 0.21 25.0  + 5.9* 
C. albicans IHEM 10284 3.19  + 0.27 47.6  + 5.5* 
C. albicans ATCC 10231 2.89  + 0.32 33.4  + 2.5* 
C. albicans IHEM 9559 3.28  + 0.15 11.5  + 3.9* 
C. albicans MUCL 29919 3.80  + 0.19 81.7  + 16.9 
C. dubliniensis IHEM 14280 3.90  + 0.21 23.3  + 2.3* 
C. glabrata MUCL 15664 3.21  + 0.19 64.4  + 13.3 
C. krusei IHEM 1796 2.73  + 0.16 20.3  + 4.5* 
C. parapsilosis IHEM 3270 3.36  + 0.22 53.2  + 8.5* 
C. tropicalis IHEM 4225 4.05  + 0.22 26.5  + 3.8* 
 459 
 460 
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Table 2. Minimal inhibitory concentrations (MIC) (mg/L) of miconazole in the absence and presence of ascorbic acid. 461 
 462 
 463 
 MIC miconazole 
(mg/L) 
MIC miconazole 
(mg/L) in the presence 
of 10 mM ascorbic acid  
Fold change in 
MIC 
C. albicans SC5314 0.063 0.250 4 
C. albicans MUCL 29800 0.031 0.125 4 
C. albicans MUCL 29981 0.031 2.000 64 
C. albicans MUCL 29903 0.063 0.250 4 
C. albicans MUCL 30112 0.063 0.500 8 
C. albicans NCYC 1467 0.063 0.500 8 
C. albicans IHEM 10284 0.125 0.125 1 
C. albicans ATCC 10231 0.125 0.250 2 
C. albicans IHEM 9559 0.125 0.250 2 
C. albicans MUCL 29919 0.125 0.125 1 
C. dubliniensis IHEM 14280 0.063 0.125 2 
C. glabrata MUCL 15664 1.000 1.000 1 
C. krusei IHEM 1796 4.000 4.000 1 
C. parapsilosis IHEM 3270 1.000 1.000 1 
C. tropicalis IHEM 4225 1.000 4.000 4 
 23 
Supplementary data :  464 
Candida albicans sessile cells stained with the Apoptosis Detection Kit 465 
Annexin V-CY3. 466 
Picture A: Untreated sessile Candida albicans cells (green fluorescence) 467 
Picture B: Untreated sessile Candida albicans cells (red fluorescence) 468 
Picture C: Miconazole-treated sessile Candida albicans cells (green fluorescence) 469 
Picture D: Miconazole-treated sessile Candida albicans cells (red fluorescence) 470 
Picture E: Miconazole and ascorbic acid treated sessile Candida albicans cells 471 
(green fluorescence) 472 
Picture F: Miconazole and ascorbic acid treated sessile Candida albicans cells 473 
(red fluorescence) 474 
Picture G: Hydrogen peroxide treated sessile Candida albicans cells (green 475 
fluorescence) 476 
Picture H: Hydrogen peroxide treated sessile Candida albicans cells (red 477 
fluorescence) 478 
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